Rhythm Pharmaceuticals, Inc. Common Stock Stock Prediction
AI-powered sentiment analysis and prediction trends for RYTM, updated each market day.
RYTM AI Sentiment
AI predicts Rhythm Pharmaceuticals, Inc. Common Stock stock is likely to increase over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Rhythm Pharmaceuticals, Inc. Common Stock
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.
Sector
Exchange
Market Cap
$5,881,390,409
Cap Tier
Employees
414
Headquarters
BOSTON, MA
Listed Since
Oct. 5, 2017
Website
RYTM Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
RYTM Volatility
Rhythm Pharmaceuticals, Inc. Common Stock has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
